Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- STNE +4.8%
Other news:
- FREY +16.3% (Publishes Shareholder Letter)
- ABOS +5.3% (entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company)
- BA +3.4% (Emirates orders nearly 100 more Boeing Widebody Airplanes; announces flydubai Ordered 30 Boeing 787 Dreamliners; announces agreement with SunExpress to buy up 90 Boeing 737 MAX Jets)
- BBIO +3.3% (presents additional clinical outcomes data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy)
- EP +3.3% (amended and restated the Bridge Loans with Empire North Dakota)
- MIST +3.1% (Presents Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023)
- LGND +3.1% (discloses finalized accounting changes subsequent to the issuance of the Company's November 8, 2023 earnings release)
- TMC +3% (The Metals Company and PAMCO sign binding MOU to complete feasibility study to process polymetallic nodules into battery metal feedstocks)
- HE +2% (amends late 10-Q filing)
- ETNB +1.9% (Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin)
- GNL +1.5% (amended equity distribution agreement) SSL +1.4% (Chairman steps down)
- IONS +1.4% (shares positive clinical update from ongoing trial of ION582 for Angelman syndrome)
- LXRX +1% (reports INPEFA Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data)
- AVIR +1% (Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023) .
Analyst comments:
- NTRA +4% (upgraded to Strong Buy from Outperform at Raymond James)
- GH +3.1% (upgraded to Outperform from Mkt Perform at Raymond James)
- ACT +2.1% (upgraded to Buy from Neutral at BofA Securities)